Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

Trial Profile

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Simvastatin (Primary) ; Zoledronic acid (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 21 Nov 2016 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2016.
    • 21 Nov 2016 Status changed from recruiting to discontinued because Principal Investigator left institution and thus study not continued.
    • 30 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top